Annotation of Pharmaceuticals and Medical Devices Agency, Japan (PMDA) label information
for dasatinib
and ABL1, BCR
Summary
The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Annotation
Please note that the information contained within this drug label annotation is sourced from Shimazawa and Ikeda (2013), whose paper provided an unofficial translation of the pharmacogenetic information contained in the PMDA package insert for research purposes.
Excerpt from the package insert for dasatinib:
Philadelphia chromosome-positive, recurrent or refractory acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the dasatinib package insert (in Japanese).
*Disclaimer: The contents of this page have not been endorsed by the PMDA and are the sole responsibility of PharmGKB.